Why would PFE create more competition for itself (Inflectra)?
With sufficient royalties and sales-milestone payments on Ixifi, PFE could make more money from the two drugs combined than they can with Inflectra alone. Note that PFE has to share Inflectra profits with Celltrion.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”